Related Experiment Video

Updated: Jun 19, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Benefits and difficulties in measuring HDL subfractions and human paraoxonase-1 activity during statin treatment

Mariann Harangi1, Ildikó Seres, János Harangi

  • 1First Department of Medicine, Medical and Health Sciences Center, University of Debrecen, Nagyerdei krt. 98, 4032, Debrecen, Hungary.

Cardiovascular Drugs and Therapy
|October 28, 2009
PubMed

Insights

Statins, widely used for cardiovascular disease prevention, may affect high-density lipoprotein (HDL) subfractions and paraoxonase-1 (PON1) activity. This review explores these effects and their clinical relevance.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Dyslipidemia, characterized by low high-density lipoprotein (HDL) cholesterol, increases cardiovascular risk.
  • Statins (HMG-CoA reductase inhibitors) are highly effective in preventing cardiovascular diseases.
  • The impact of statins on HDL subfractions and HDL-associated enzymes like paraoxonase-1 (PON1) remains incompletely understood.

Purpose of the Study:

  • To review the effects of statins on HDL subfractions.
  • To examine the influence of statins on paraoxonase-1 (PON1) activity.
  • To discuss the clinical significance of these observed changes.

Main Methods:

  • Literature review of studies investigating statin effects on HDL and PON1.
  • Analysis of data on HDL subfractions and PON1 activity in patients using statins.
  • Discussion of methodological challenges in assessing HDL subfractions and PON1 activity.

Main Results:

  • Statins may alter HDL subfractions, though effects on overall HDL-cholesterol are modest.
  • Evidence suggests statins can impact paraoxonase-1 (PON1) activity.
  • The clinical implications of these alterations require further investigation.

Conclusions:

  • Statins exert complex effects on HDL metabolism beyond total cholesterol levels.
  • Understanding statin-induced changes in HDL subfractions and PON1 is crucial for assessing cardiovascular risk.
  • Standardization of methodologies for HDL subfraction and PON1 activity assays is needed.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...